Skip to main content
. 2013 May 23;108(12):2549–2556. doi: 10.1038/bjc.2013.245

Figure 2.

Figure 2

Necrosis evaluation. (A) Mean necrosis percentage in controls vs treated patients. (B) Mean necrosis percentage in the chemotherapy group (CT-Only) vs the bevacizumab group (CT+bev).